Jivi (Damoctocog Alfa Pegol)

Damoctocog alfa pegol is a PEGylated recombinant factor VIII that restores functional factor VIII activity in the intrinsic coagulation pathway. By forming the tenase complex with factor IXa, it enables conversion of factor X to Xa, leading to thrombin generation and stable fibrin clot formation in individuals lacking endogenous factor VIII.

The dosage of Jivi is individualized by the prescribing healthcare professional based on the patient’s weight, severity of factor VIII deficiency, type of bleed, and surgical requirements. Dosing regimens are calculated to achieve target factor VIII activity levels and are adjusted according to clinical response and laboratory monitoring.

Safety data for Jivi in pregnant or lactating women are limited, and the product is classified as pregnancy category unknown. Use during pregnancy or breastfeeding should only occur if the potential benefit justifies the potential risk, and decisions should be made by the treating physician in consultation with obstetric specialists.

To place an order, submit an enquiry on the Jivi product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and the necessary import documentation.

Jivi is a PEGylated recombinant factor VIII, offering an extended half‑life compared with standard non‑PEGylated factor VIII concentrates. This longer circulation time can reduce infusion frequency for prophylaxis, while maintaining comparable efficacy in controlling bleeding. Choice of product depends on individual patient needs, inhibitor status, and physician preference.

Jivi must be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. Do not freeze or shake the vial. If temperature excursions occur, discard the product according to the manufacturer’s guidelines. Proper cold‑chain management is essential to maintain product stability.

Jivi is supplied as a sterile solution for injection and is administered intravenously. The infusion is given through a peripheral or central venous line, typically over several minutes, depending on the prescribed dose and patient tolerance. Administration should be performed by qualified healthcare personnel following aseptic technique.

The most serious risks include the development of inhibitory antibodies that neutralize factor VIII activity, severe allergic or anaphylactic reactions, and rare thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Patients should be monitored closely for signs of these complications, and immediate medical attention is required if they occur.

Jivi is contraindicated in individuals with known hypersensitivity to Damoctocog alfa pegol or any of the excipients in the formulation. Patients with a history of severe allergic reactions to factor VIII products should avoid Jivi, and alternative therapies should be considered under medical supervision.